Noemi Reguart/X
Mar 26, 2025, 13:32
Noemi Reguart: MARIPOSA (Ami + Lazer) show OS superiority over SoC in 1st line EGFRm NSCLC
Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“Osimertinib BEATEN!!
MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, p<0.005, 3yr 60% vs 51%) and landmark 3-yr icPFS improvement (36% vs 18%)—first combo to show OS superiority over SoC, extending OS beyond 3 years in first line EGFRm NSCLC.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 06:09